Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant <i>Brca1</i> Proficient and Deficient Murine Ovarian Cells

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant <i>Brca1</i> Proficient and Deficient Murine Ovarian Cells

Background. Poly(ADP-ribose) polymerases inhibitor (PARPi) have shown clinical efficacy in ovarian carcinoma, especially in those harboring defects in homologous recombination (HR) repair, including <i>BRCA1</i> and <i>BRCA2</i> mutated tumors. There is increasing evidence ho...

Full description

Bibliographic Details
Main Authors: Michela Chiappa, Federica Guffanti, Martina Anselmi, Monica Lupi, Nicolò Panini, Lisa Wiesmüller, Giovanna Damia
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
ovarian carcinoma
homologous recombination
PARPi
olaparib resistance
Online Access:https://www.mdpi.com/2072-6694/14/7/1807

Internet

https://www.mdpi.com/2072-6694/14/7/1807

Similar Items